BioInvent International AB (BOVNF)
OTHER OTC:BOVNF
BOVNF Stock Chart & Stats
$3.29
$0.00(0.00%)
At close: 4:00 PM EDT
$3.29
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$3.29 - $3.29
Previous CloseN/A
Volume3.00
Average Volume (3M)0.00
Market Cap
$169.23M
Enterprise Value$1.83B
Total Cash (Recent Filing)$456.48M
Total Debt (Recent Filing)$6.25M
Price to Earnings (P/E)―
Beta0.18
Next Earnings
Aug 27, 2026EPS Estimate
-0.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.09
Shares Outstanding65,804,360
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.26
Price to Book (P/B)3.47
Price to Sales (P/S)8.54
P/FCF Ratio-7.58
Enterprise Value/Market Cap10.80
Enterprise Value/Revenue8.39
Enterprise Value/Gross Profit8.52
Enterprise Value/Ebitda-5.60
Forecast
1Y Price Target
$9.59Price Target Upside191.59% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.8
Revenue Forecast (FY)$15.39M
Bulls Say, Bears Say
Bulls Say
Proprietary Discovery PlatformBioInvent’s ownership of proprietary antibody discovery and validation platforms supports a durable, scalable drug-discovery engine. This enables repeatable generation of novel candidates, strengthens partnership value propositions, and supports long-term licensing and milestone revenue potential independent of single-drug success.
Low Financial LeverageVery low debt reduces refinancing and interest-rate vulnerabilities, preserving strategic optionality for R&D funding, partnerships, or opportunistic M&A. A low-leverage profile provides a multi-quarter runway buffer as the company executes clinical programs and seeks milestone-based inflows.
High Gross Margins On RevenueNear-100% gross margins reflect low incremental COGS for discovery and licensing revenues, implying that incremental partner or product revenue would largely drop to the operating line. This structural margin profile supports scalable profitability once operating expenses and cash burn are controlled.
Bears Say
Persistent Cash BurnSustained negative operating and free cash flow of roughly -260M TTM implies recurring external funding needs. Over multiple quarters this erodes equity, forces dilutive financings or costly partnerships, and constrains the company’s ability to self-fund late-stage development or commercialization activities.
Large Operating And Net LossesOperating and net losses at ~1.5x revenue indicate a structural gap between current income and expense base. Unless offset by material partner milestones or product revenue, these losses will continue to degrade equity and limit reinvestment capacity, pressuring strategic flexibility and long-term sustainability.
Uneven, Milestone-driven RevenueRevenue volatility tied to milestone timing creates uncertain cash inflows and complicates multi-period planning. Milestone-driven top line makes forecasting and operational scaling harder, increasing reliance on external financing during dry spells and raising execution risk for sustained growth.
BioInvent International AB News
BOVNF FAQ
What was BioInvent International AB’s price range in the past 12 months?
BioInvent International AB lowest stock price was $3.29 and its highest was $3.29 in the past 12 months.
What is BioInvent International AB’s market cap?
BioInvent International AB’s market cap is $169.23M.
When is BioInvent International AB’s upcoming earnings report date?
BioInvent International AB’s upcoming earnings report date is Aug 27, 2026 which is in 72 days.
How were BioInvent International AB’s earnings last quarter?
BioInvent International AB released its earnings results on Apr 29, 2026. The company reported -$0.202 earnings per share for the quarter, the consensus estimate of -$0.202 by $0.
Is BioInvent International AB overvalued?
According to Wall Street analysts BioInvent International AB’s price is currently Undervalued.
Does BioInvent International AB pay dividends?
BioInvent International AB does not currently pay dividends.
What is BioInvent International AB’s EPS estimate?
BioInvent International AB’s EPS estimate is -0.2.
How many shares outstanding does BioInvent International AB have?
BioInvent International AB has 65,804,360 shares outstanding.
What happened to BioInvent International AB’s price movement after its last earnings report?
BioInvent International AB reported an EPS of -$0.202 in its last earnings report, expectations of -$0.202. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of BioInvent International AB?
Currently, no hedge funds are holding shares in BOVNF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
BioInvent International AB
BioInvent International AB (publ) is a clinical-stage Swedish company dedicated to discovering, researching, and developing immunomodulatory antibodies for global cancer treatment, with reach across Sweden, Europe, the United States, and Japan. Its most advanced therapeutic candidate, BI-1206, targets non-Hodgkin lymphoma and various solid tumors. The company's diverse pipeline also features developments aimed at tumor-associated myeloid cells and cancer-associated regulatory T cells, which play a role in modulating the immune system, alongside BT-001 for solid tumors. Furthermore, BioInvent is progressing BI-1808 and BI-1910, a pair of anti-TNFR2 antibodies, designed to combat solid tumors and cutaneous T-cell lymphoma. Strategic collaborations are integral to its operations; these include a partnership with Pfizer Inc. for antibody development against tumor-associated myeloid cells, a co-development effort with Transgene involving multi-functional oncolytic viruses for solid tumors, and an agreement with Merck for the clinical advancement and supply of BI-1808. Established in 1996, BioInvent is based in Lund, Sweden.
BOVNF Company Deck
BOVNF Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents multiple strong clinical data points (notably BI-1808 in ovarian cancer and CTCL, and BI-1206 in NHL) with supportive safety and clear near-term catalysts and collaborations with Merck and AstraZeneca. Financially, Q4 sales fell sharply due to lower contract production while full-year sales increased materially driven by one-time items; operating costs and losses rose and the company states it is financed for only the next 12 months, meaning further financing or partnering will be needed to sustain a larger pivotal development plan. Overall, the positive clinical momentum and strategic partnerships outweigh short-term financial and execution risks, but upcoming readouts will be critical for de-risking future funding and pivotal starts.View all BOVNF earnings summariesBOVNF Stock 12 Month Forecast
Average Price Target
$9.59
▲(191.59% Upside)
Technical Analysis
Hansa Biopharma AB
―
Saniona AB
―
Vicore Pharma Holding AB
―
Xspray Pharma AB
―
Cantargia AB
―
Ownership Overview
―
Insiders
<0.01% Mutual Funds
― Other Institutional Investors
99.96% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---